Alx Oncology Holdings (ALXO) Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings has reported Accumulated Expenses for 8 years, with the latest figure at $1.8 million in Q1 2026.

• Quarterly Accumulated Expenses fell 86.14% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 86.14% YoY) and the FY2025 annual result came in at $14.4 million, up 171.81% from the prior year.
• Accumulated Expenses slipped to $1.8 million in Q1 2026 per ALXO's latest filing, from $14.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $30.1 million in Q2 2024 and troughed at $1.8 million in Q1 2026.
• A 5-year average of $9.1 million and a median of $4.8 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses soared 624.57% in 2023, then tumbled 86.14% in 2026.
• Over 5 years, Accumulated Expenses stood at $3.7 million in 2022, then jumped by 624.57% to $26.9 million in 2023, then slumped by 80.25% to $5.3 million in 2024, then soared by 171.81% to $14.4 million in 2025, then tumbled by 87.49% to $1.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.8 million, $14.4 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.